Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Ver. Summary Created by Modification Content Size Created at Operation
1 + 694 word(s) 694 2020-12-15 07:35:47

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Xu, R. Primary Macronodular Adrenal Hyperplasia. Encyclopedia. Available online: (accessed on 08 December 2023).
Xu R. Primary Macronodular Adrenal Hyperplasia. Encyclopedia. Available at: Accessed December 08, 2023.
Xu, Rita. "Primary Macronodular Adrenal Hyperplasia" Encyclopedia, (accessed December 08, 2023).
Xu, R.(2020, December 24). Primary Macronodular Adrenal Hyperplasia. In Encyclopedia.
Xu, Rita. "Primary Macronodular Adrenal Hyperplasia." Encyclopedia. Web. 24 December, 2020.
Primary Macronodular Adrenal Hyperplasia

Primary macronodular adrenal hyperplasia (PMAH) is a disorder characterized by multiple lumps (nodules) in the adrenal glands, which are small hormone-producing glands located on top of each kidney. These nodules, which usually are found in both adrenal glands (bilateral) and vary in size, cause adrenal gland enlargement (hyperplasia) and result in the production of higher-than-normal levels of the hormone cortisol. Cortisol is an important hormone that suppresses inflammation and protects the body from physical stress such as infection or trauma through several mechanisms including raising blood sugar levels.

genetic conditions

1. Introduction

PMAH typically becomes evident in a person's forties or fifties. It is considered a form of Cushing syndrome, which is characterized by increased levels of cortisol resulting from one of many possible causes. These increased cortisol levels lead to weight gain in the face and upper body, fragile skin, bone loss, fatigue, and other health problems. However, some people with PMAH do not experience these signs and symptoms and are said to have subclinical Cushing syndrome.

2. Frequency

PMAH is a rare disorder. It is present in less than 1 percent of cases of endogenous Cushing syndrome, which describes forms of Cushing syndrome caused by factors internal to the body rather than by external factors such as long-term use of certain medicines called corticosteroids. The prevalence of endogenous Cushing syndrome is about 1 in 26,000 people.

3. Causes

In about half of individuals with PMAH, the condition is caused by mutations in the ARMC5 gene. This gene provides instructions for making a protein that is thought to act as a tumor suppressor, which means that it helps to prevent cells from growing and dividing too rapidly or in an uncontrolled way. ARMC5 gene mutations are believed to impair the protein's tumor-suppressor function, which allows the overgrowth of certain cells. It is unclear why this overgrowth is limited to the formation of adrenal gland nodules in people with PMAH.

PMAH can also be caused by mutations in the GNAS gene. This gene provides instructions for making one component, the stimulatory alpha subunit, of a protein complex called a guanine nucleotide-binding protein (G protein). The G protein produced from the GNAS gene helps stimulate the activity of an enzyme called adenylate cyclase. This enzyme is involved in controlling the production of several hormones that help regulate the activity of certain endocrine glands, including the adrenal glands. The GNAS gene mutations that cause PMAH are believed to result in an overactive G protein. Research suggests that the overactive G protein may increase levels of adenylate cyclase and result in the overproduction of another compound called cyclic AMP (cAMP). An excess of cAMP may trigger abnormal cell growth and lead to the adrenal nodules characteristic of PMAH.

Mutations in other genes, some of which are unknown, can also cause PMAH.

4. Inheritance

People with PMAH caused by ARMC5 gene mutations inherit one copy of the mutated gene in each cell. The inheritance is considered autosomal dominant because one copy of the mutated gene is sufficient to make an individual susceptible to PMAH. However, the condition develops only when affected individuals acquire another mutation in the other copy of the ARMC5 gene in certain cells of the adrenal glands. This second mutation is described as somatic. Instead of being passed from parent to child, somatic mutations are acquired during a person's lifetime and are present only in certain cells. Because somatic mutations are also required for PMAH to occur, some people who have inherited the altered ARMC5 gene never develop the condition, a situation known as reduced penetrance.

When PMAH is caused by GNAS gene mutations, the condition is not inherited. The GNAS gene mutations that cause PMAH are somatic mutations. In PMAH, the gene mutation is believed to occur early in embryonic development. Cells with the mutated GNAS gene can be found in both adrenal glands.

5. Other Names for This Condition

  • ACTH-independent macronodular adrenal hyperplasia
  • ACTH-independent macronodular adrenocortical hyperplasia
  • adrenal Cushing syndrome due to AIMAH
  • adrenocorticotropic hormone-independent macronodular adrenal hyperplasia
  • corticotropin-independent macronodular adrenal hyperplasia
  • PMAH
  • primary bilateral macronodular adrenal hyperplasia


  1. Alencar GA, Lerario AM, Nishi MY, Mariani BM, Almeida MQ, Tremblay J, Hamet P,Bourdeau I, Zerbini MC, Pereira MA, Gomes GC, Rocha Mde S, Chambo JL, Lacroix A, Mendonca BB, Fragoso MC. ARMC5 mutations are a frequent cause of primarymacronodular adrenal Hyperplasia. J Clin Endocrinol Metab. 2014Aug;99(8):E1501-9. doi: 10.1210/jc.2013-4237.
  2. Assié G, Libé R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau O,Lefèvre L, Sibony M, Guignat L, Rodriguez S, Perlemoine K, René-Corail F,Letourneur F, Trabulsi B, Poussier A, Chabbert-Buffet N, Borson-Chazot F,Groussin L, Bertagna X, Stratakis CA, Ragazzon B, Bertherat J. ARMC5 mutations inmacronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med. 2013 Nov 28;369(22):2105-14. doi: 10.1056/NEJMoa1304603.
  3. De Venanzi A, Alencar GA, Bourdeau I, Fragoso MC, Lacroix A. Primary bilateralmacronodular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes. 2014Jun;21(3):177-84. doi: 10.1097/MED.0000000000000061. Review.
  4. Elbelt U, Trovato A, Kloth M, Gentz E, Finke R, Spranger J, Galas D, Weber S, Wolf C, König K, Arlt W, Büttner R, May P, Allolio B, Schneider JG. Molecular andclinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germlineand somatic mutations are associated with both primary macronodular adrenalhyperplasia and meningioma. J Clin Endocrinol Metab. 2015 Jan;100(1):E119-28.doi: 10.1210/jc.2014-2648.
  5. Faucz FR, Zilbermint M, Lodish MB, Szarek E, Trivellin G, Sinaii N, Berthon A,Libé R, Assié G, Espiard S, Drougat L, Ragazzon B, Bertherat J, Stratakis CA.Macronodular adrenal hyperplasia due to mutations in an armadillo repeatcontaining 5 (ARMC5) gene: a clinical and genetic investigation. J ClinEndocrinol Metab. 2014 Jun;99(6):E1113-9. doi: 10.1210/jc.2013-4280.
  6. Fragoso MC, Domenice S, Latronico AC, Martin RM, Pereira MA, Zerbini MC, LuconAM, Mendonca BB. Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1gene. J Clin Endocrinol Metab. 2003 May;88(5):2147-51.
  7. Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, Hotu C,Oftedal BE, Cutfield R, Adelson DL, Braund WJ, Gordon RD, Rees DA, Grossman AB,Torpy DJ, Scott HS. ARMC5 mutations are common in familial bilateral macronodularadrenal hyperplasia. J Clin Endocrinol Metab. 2014 Sep;99(9):E1784-92. doi:10.1210/jc.2014-1265.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 298
Entry Collection: MedlinePlus
Revision: 1 time (View History)
Update Date: 24 Dec 2020